Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Transcend Therapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, which naturally means that the entire active portfolio is under the review of one individual. The application is also located within 1 distinct art unit, indicating a very focused technical area for the company's current patent prosecution.
SHIM, DAVID M. is the busiest examiner for the company, as he is currently responsible for the 1 pending office action. Because there is only 1 pending office action in total, SHIM, DAVID M. is the sole examiner with whom the company is currently interacting. This ratio between the total actions and the busiest examiner's workload represents a complete concentration of the company's active prosecution.
The involvement of only 1 distinct art unit and 1 distinct examiner for the pending office action simplifies the company's immediate legal focus. Practitioners only need to navigate the specific standards of one technical division and the individual style of SHIM, DAVID M. While the portfolio is currently limited, the outcome of this case is the primary concern for the company's interests in Biotechnology & Pharmaceuticals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19429715 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19429715 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | — | Pending | Dec 22, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTranscend Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David M. Shim has the most, with 1 of Transcend Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
